Comparative effects of Folfirinox and Gemcitabine/nab-paclitaxel as first and second line chemotherapy for metastatic pancreatic cancer: single choice or sequence

被引：0
|
作者：
Caponnetto, S. [1 ]
Gelibter, A. [2 ]
Mosillo, C. [2 ]
Magri, V. [2 ]
Scagnoli, S. [2 ]
Pomati, G. [2 ]
Piesco, G. [2 ]
Verkhovskaya, S. [2 ]
Pisegna, S. [2 ]
Sirgiovanni, G. [2 ]
Napoli, V. [2 ]
Buscicchio, D. [2 ]
Iannantuono, G. M. [2 ]
Marinelli, D. [2 ]
Mammone, G. [2 ]
Pannunzio, S. [2 ]
Nicolo, E. [2 ]
Stefani, A. [2 ]
Astorino, V. [2 ]
Mancini, M. [2 ]
Cortesi, E. [2 ]
机构：
[1] Univ Roma La Sapienza, Oncol Med B, Policlin Umberto I, Rome, Italy
[2] Policlin Umberto 1, Oncol Med B, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
D27
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer
    Guo Xi
    Xu Yaolin
    Ji Yuan
    Fan Yue
    Wang Dansong
    Jin Dayong
    Zhuang Rongyuan
    Wu Lili
    Lou Wenhui
    Zhou Yuhong
    Department of Medical Oncology
    Department of General Surgery
    Department of Pathology
    Department of Traditional Chinese Medicine
    Department of Radiotherapy
    胰腺病学杂志（英文）, 2020, 03 (01) : 35 - 41
  • [32] FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
    Cho, In Rae
    Kang, Huapyong
    Jo, Jung Hyun
    Lee, Hee Seung
    Chung, Moon Jae
    Park, Jeong Youp
    Park, Seung Woo
    Song, Si Young
    An, Chansik
    Park, Mi-Suk
    Bang, Seungmin
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 12 (02) : 182 - 194
  • [33] FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study
    Servetto, Alberto
    Santaniello, Antonio
    Napolitano, Fabiana
    Foschini, Francesca
    Marciano, Roberta
    Cascetta, Priscilla
    Amato, Anna Rita
    Augurio, Maria Rosaria
    Maresca, Lucia
    De Placido, Pietro
    De Placido, Sabino
    Formisano, Luigi
    Bianco, Roberto
    FUTURE ONCOLOGY, 2022, 18 (21) : 2643 - 2654
  • [34] Comparative effectiveness of gemcitabine vs gemcitabine plus nab-paclitaxel vs FOLFIRINOX for unresectable pancreatic cancer
    Yamamoto, Shun
    Ueno, Hideki
    Tanaka, Midori
    Inagaki, Yuji
    Ohba, Akihiro
    Sakamoto, Yasunari
    Kondo, Shunsuke
    Morizane, Chigusa
    Okusaka, Takuji
    ANNALS OF ONCOLOGY, 2017, 28
  • [35] FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
    In Rae Cho
    Huapyong Kang
    Jung Hyun Jo
    Hee Seung Lee
    Moon Jae Chung
    Jeong Youp Park
    Seung Woo Park
    Si Young Song
    Chansik An
    Mi-Suk Park
    Seungmin Bang
    World Journal of Gastrointestinal Oncology, 2020, 12 (02) : 182 - 194
  • [36] Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
    Mita, Naoki
    Iwashita, Takuji
    Uemura, Shinya
    Yoshida, Kensaku
    Iwasa, Yuhei
    Ando, Nobuhiro
    Iwata, Keisuke
    Okuno, Mitsuru
    Mukai, Tsuyoshi
    Shimizu, Masahito
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
  • [37] Efficacy of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX as first line chemotherapy for metastatic pancreatic cancer (mPC): Real world experiences.
    Hwang, Inhwang
    Kang, Jihoon
    Yoo, Changhoon
    Kim, Kyu-Pyo
    Jeong, Jae Ho
    Chang, Heung-Moon
    Ryoo, Baek-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [38] Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer Propensity Score Matching
    Mie, Takafumi
    Sasaki, Takashi
    Takeda, Tsuyoshi
    Fukuda, Koshiro
    Furukawa, Takaaki
    Yamada, Yuto
    Kasuga, Akiyoshi
    Matsuyama, Masato
    Ozaka, Masato
    Sasahira, Naoki
    PANCREAS, 2021, 50 (04) : 595 - 601
  • [39] Efficacy and safety of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX (FFX) as first line chemotherapy for metastatic pancreatic cancer (mPC): Retrospective analysis
    Lee, K.
    Hwang, I.
    Kang, J.
    Yoo, C.
    Kim, K-P.
    Jeong, J. H.
    Chang, H-M.
    Ryoo, B-Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [40] Gemcitabine plus nab-paclitaxel as second line and beyond for metastatic pancreatic cancer (MPC): A single institution retrospective analysis
    Zaniboni, Alberto
    Bertocchi, Paola
    Abeni, Chiara
    Ogliosi, Chiara
    Rizzi, Anna
    Rota, Luigina
    Di Blasi, Brunelle
    Prochllo, Tiziana
    Aroldl, Francesca
    Meriggi, Fausto
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345